interscalene block
Procedure15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
NCT Number: NCT03718858
This is a randomized controlled trial evaluating the impact of interscalene block on worsening of upper airway collapse in sleep disordered breathing for patients undergoing ambulatory shoulder surgery.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Women's College Hospital, Toronto, ON Ontario, Canada
Sleep disordered Breathing (SDB), closely associated with obesity, is a highly prevalent, serious, and often unrecognized breathing disorder resulting from repeated upper airway collapse, decreased oxygen levels, and a very high risk of life threatening complications at the time of surgery. Current guidelines recommend using regional as opposed to general anesthesia in SDB patients to minimize risks and the use of strong narcotic medications. It is unclear whether interscalene block in use for analgesia (pain relief) may actually worsen the severity of SDB by invariably freezing the phrenic nerve, thereby temporarily paralyzing the diaphragm.
This novel clinical trial will examine whether or not ISB increases the rate of upper airway obstruction or collapse during sleep and other dangerous postoperative complications seen in patients with SDB following shoulder surgeries.
The Primary Objective of the study is to evaluate the impact of ISB on the oxygen desaturation index (sleep apnea severity) in untreated SDB patients undergoing ambulatory shoulder surgery compared to patients who do not receive ISB.
Secondary Objectives are: 1) To evaluate the impact of hemidiaphragmatic paresis on impairment in pulmonary function; 2) To evaluate the impact of impairment in pulmonary function on the oxygen desaturation index (ODI); 3) To assess the incidence of important perioperative clinical outcomes such as hypoxemia, recurrent respiratory events, delayed discharge, and resource utilization in SDB patients undergoing ambulatory shoulder surgery compared to patients who do not receive ISB; and 4) To assess important analgesia related outcomes such as: time to onset of pain, intraoperative and postoperative opioid consumption, hourly and daily VAS pain scores, opioid related side effects, patient satisfaction with analgesia, and presence/absence of nerve block complications.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to Superior Trunk Nerve.
Time frame: Time of measurements will be at baseline (pre operatively) and within 24 hours post-operatively (night of surgery)
All patients will undergo a portable overnight oximetry study at home to establish the baseline oxygen saturation measured hourly. Oxygen Desaturation Index (ODI), which is defined as a 4% drop in oxygenation from the baseline, and calculated as events occurring per hour during the recording time; the minimum and mean oxygen saturation ; and the cumulative total of recoded time below an oxygen saturation of 90%, CT90). Patients with preoperative ODI with more than a score of 10 will be considered at risk of SDB. A change from baseline will be examined and compared between the two groups.
Time frame: Time of measurements will be within 1 hour before surgery, and within 1 hour after surgery. It will take around 10-15 minutes.
Rate of diaphragmatic function (complete, partial, or none) will be assessed before and after surgery using M-Mode Ultrasound. Assessment will be performed during quiet breathing, sniffing, and deep breathing. After surgery diaphragmatic paresis will be indicated by a flat trace (absence of excursion) with quiet and deep breathing and/or with paradoxical motion. Measurement of amplitude of excursion will be made when partial paresis is observed. Using the sniff maneuver, complete hemi-diaphragmatic paresis (reduction of >75% from baseline) and partial paresis (reduction of 25-75%from baseline) will be recorded. Rate will be assessed in the basal state (i.e. before regional anesthesia) to establish a baseline, and again in the post-operative period.
Time frame: Time of measurements will be within 1 hour before surgery, and within 1 hour after surgery. It will take around 5-10 minutes.
Change in pulmonary function tests [Forced vital capacity (FVC), forced expiratory volume in 1s (FEV1), Expiratory reserve volume (ERV) and peak expiratory flow (PEF) ], between before and after surgery will be measured by bedside spirometry
Time frame: Within 24 hours of the time of surgery
Respiratory events in recovery room (Oxygen saturation < 90% (3 episodes), bradypnea < 8 breaths / min (3 episodes), apnea ≥ 10s (1 episode) will be recorded.
Time frame: 8 hours and 24 hours after surgery.
Measurement of hourly and daily Visual Analogue Scale (VAS) pain scores. VAS: 10cm scale where 0=no pain, 10=worst pain.
Time frame: Day 1 of surgery.
Opioid and other pain killers consumption will be recorded intra and post-operatively
Time frame: 8 hours and 24 hours after surgery.
A follow up call will be made on day 1 and day 30 to collect overall satisfaction with pain control. Overall satisfaction will be assessed on a 7-point Likert scale of 1-not at all satisfied with pain control, 2-mostly unsatisfied with pain control, 3-slightly unsatisfied with pain control, 4-no opinion, 5-slightly satisfied with pain control, 6-mostly satisfied with pain control, 7-completely satisfied with pain control
Women's College Hospital
Other
Evaluating the Impact of Interscalene Brachial Plexus Block on Sleep-disordered Breathing in Patients Undergoing Ambulatory Shoulder Surgery. A Two-arm, Prospective, Parallel, Double Blind Randomized -Controlled Trial
Acronym: OSA-ISB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01918007
Apnea, Dyssomnias
Athens, Greece
View Trial DetailsNCT00922168
Apnea, Central Sleep Apnea
Baltimore, Maryland, United States
View Trial DetailsNCT03964376
Apnea, Dyssomnias
Toronto, Ontario, Canada
View Trial DetailsNCT03226652
Apnea, Cardiovascular Diseases
London, United Kingdom
View Trial Details